Ligand Pharmaceuticals LGND Current contingent liabilities
Current contingent liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:CurrentPortionOfLiabilityForContingentValueRights.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's current contingent liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's current contingent liabilities?
- Ligand Pharmaceuticals (LGND) reported current contingent liabilities of $277K in Q1 2026.
- How has Ligand Pharmaceuticals's current contingent liabilities changed year-over-year?
- Ligand Pharmaceuticals's current contingent liabilities decreased by 81.3% year-over-year, from $1.48M to $277K.
- What is the long-term trend for Ligand Pharmaceuticals's current contingent liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's current contingent liabilities has grown at a -62.7% compound annual growth rate (CAGR), from $39.88M to $287K.
- What does current contingent liabilities mean?
- This represents the short-term obligation associated with contingent payments, such as earn-outs or milestone-based liabilities, due within one year. It reflects the immediate cash outflow requirements linked to past acquisitions or licensing agreements. Managing this is essential for maintaining short-term liquidity and meeting contractual obligations.